Pharmaceuticals have been fairly unloved by investors for a number of years. However, as the equity rally continues and prices increase, to me, a number of these companies look incredibly cheap.The healthcare story is one many can relate...
Pharmaceuticals have been fairly unloved by investors for a number of years. However, as the equity rally continues and prices increase, to me, a number of these companies look incredibly cheap.The healthcare story is one many can relate to; demographics are changing, people are living longer as medicine and healthcare technology advances. Furthermore, the developing consumer demand in emerging and frontier markets for pharmaceutical goods offers and excellent growth opportunity.Although there are a number of companies worth investing in, AstraZeneca (AZN), the UK's second largest drug maker, is in a great position to offer significant upside in both its share price and earnings. Over the past few years there have been concerns with Patent Cliffs as a number of patents for blockbuster drugs created in the late 1990s run out. The loss in earnings can be significant, hence the overly suppressed valuations. This however does not detract